Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Stone

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Antimicrobial Agents and Chemotherapy|April 4, 1998
Single-dose pharmacokinetics of indinavir and the effect of foodK C Yeh, P J Deutsch, H Haddix, et al.
Clinical Pharmacology and Therapeutics|December 31, 2010
Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial designM L Reitman, X Chu, X Cai, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 30, 2016
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced MelanomaM S Chatterjee, J Elassaiss-Schaap, A Lindauer, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
Spinal Cord|June 8, 2011
The development of evidence-informed physical activity guidelines for adults with spinal cord injuryK A Martin Ginis, A L Hicks, A E Latimer, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Antimicrobial Agents and Chemotherapy|April 4, 1998
Single-dose pharmacokinetics of indinavir and the effect of foodK C Yeh, P J Deutsch, H Haddix, et al.
Clinical Pharmacology and Therapeutics|December 31, 2010
Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial designM L Reitman, X Chu, X Cai, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 30, 2016
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced MelanomaM S Chatterjee, J Elassaiss-Schaap, A Lindauer, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
Spinal Cord|June 8, 2011
The development of evidence-informed physical activity guidelines for adults with spinal cord injuryK A Martin Ginis, A L Hicks, A E Latimer, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Pageof 8